Athira Pharma Inc.

AI Score

XX

Unlock

0.33
-0.00 (-0.63%)
At close: Mar 24, 2025, 3:59 PM
0.34
2.09%
After-hours: Mar 24, 2025, 07:51 PM EDT
-0.63%
Bid 0.33
Market Cap 12.82M
Revenue (ttm) n/a
Net Income (ttm) -98.35M
EPS (ttm) -2.52
PE Ratio (ttm) -0.13
Forward PE -0.32
Analyst Hold
Ask 0.35
Volume 58,840
Avg. Volume (20D) 225,543
Open 0.33
Previous Close 0.33
Day's Range 0.32 - 0.34
52-Week Range 0.30 - 3.67
Beta 3.01

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkins...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2020
Employees 26
Stock Exchange NASDAQ
Ticker Symbol ATHA
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for ATHA stock is "Hold." The 12-month stock price forecast is $11.25, which is an increase of 3325.70% from the latest price.

Stock Forecasts
4 months ago
-12.01%
Althira Pharma shares are trading lower after the ... Unlock content with Pro Subscription
5 months ago
+15.73%
Athira Pharma shares are trading higher after the company announced it will present results from its Phase 2/3 LIFT-AD clinical trial of Fosgonimeton to treat Alzheimer's disease.